Key Phase III clinical study of Therapy Keytruda, Amesa East PD-1 immunotherapy, reaches the main end of total survival

recently, Mercadon announced that pD-1 immunotherapy Keytruda (pembrolizumab) single-drug first-line treatment of tumor cell expression PD-L1 (combined ratio score of 20) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) critical phase III KEYNOTE clinical study-048 (NCT02358031) has reached the primary survival phase (OS)related studies
a randomized, open-label phase III study to assess the efficacy and efficacy of Keytruda as a combination of monodotherapy or combination therapy with platinum chemotherapy (cisplatin or cacrea) and 5-fluoromyache compared to the current HNSCC first-line treatment standard care regimen Erbitux (cetuximab, citoxia) and platinum-containing chemotherapy (cisplatin or caucin) and 5-fluorine chemotherapythe study's common primary endpoints were Total Lifetime (OS) and Progression Less (PFS)secondary endpoints include: PFS survival rate for 6th or 12th month, objective remission rate (ORR), overall lifehealth(state quality/European Cancer Research and Treatment Organization (EORTC) quality of life questionnaire quality questionnaire quality of life scale deterioration timestudy 825 cases were randomly assigned to receive: (1) Keytruda monotherapy (200mg, 3 weeks of one course, intravenous infusion for the first day of each course, continuous treatment for 24 months) ;(2) Keytruda plus chemotherapy-included platinum-5-fluorourethane combination therapy; (3) Erbitux plus platinum-included chemotherapy-5-fluorine urethane combination therapyThe medium-termanalysisconducted by theIndependent Data Monitoring Committee (DMC) showed a significant extension of OS in the Keytruda single-drug therapy group compared to the Erbitux-platinum-containing chemotherapy-5-fluorourethane combination therapy groupAt the time of the interim analysis, the common primary endpoint PFS in patients with CPS s20 had not yet been reachedthe study, Keytruda's safety was consistent with previously reported studies involving HNSCC patients